NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $68.61 +0.04 (+0.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$68.24▼$69.8550-Day Range$56.92▼$68.6152-Week Range$50.27▼$70.36Volume2.19 million shsAverage Volume2.55 million shsMarket Capitalization$15.41 billionP/E Ratio20.79Dividend YieldN/APrice Target$73.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Incyte alerts: Email Address Incyte MarketRank™ Stock AnalysisAnalyst RatingHold2.39 Rating ScoreUpside/Downside6.8% Upside$73.25 Price TargetShort InterestHealthy5.70% of Shares Sold ShortDividend StrengthN/ASustainability-2.63Upright™ Environmental ScoreNews Sentiment0.98Based on 18 Articles This WeekInsider TradingSelling Shares$1.79 M Sold Last QuarterProj. Earnings Growth25.68%From $3.66 to $4.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector70th out of 936 stocksCommercial Physical Research Industry3rd out of 12 stocks 2.2 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageIncyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.70% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 24.34%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 37.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Janus-associated kinase (JAK) inhibitors", "Ponatinib", and "Tafasitamab" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -2.63. Previous Next 3.3 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Incyte this week, compared to 8 articles on an average week.Search InterestOnly 11 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows10 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,786,941.00 in company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 25.68% in the coming year, from $3.66 to $4.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 20.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 20.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.18.Price to Earnings Growth RatioIncyte has a PEG Ratio of 1.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Incyte Stock (NASDAQ:INCY)Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More INCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCY Stock News HeadlinesJuly 18, 2024 | insidertrades.comIncyte Co. (NASDAQ:INCY) EVP Barry P. Flannelly Sells 1,306 SharesJuly 12, 2024 | insidertrades.comIncyte Co. (NASDAQ:INCY) EVP Sells $488,880.00 in StockJuly 26, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 26 at 2:47 AM | markets.businessinsider.comEQS-News: Substantial pipeline progress at several portfolio companies offsets rate-related market volatilityJuly 25 at 12:03 PM | gurufocus.comIncyte Corp (INCY)'s Winning Formula: Financial Metrics and Competitive StrengthsJuly 23 at 3:51 AM | finance.yahoo.comAMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASESJuly 22, 2024 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) Given Average Recommendation of "Hold" by BrokeragesJuly 20, 2024 | americanbankingnews.comFY2025 EPS Estimates for Incyte Co. (NASDAQ:INCY) Boosted by AnalystJuly 26, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 19, 2024 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) EVP Sells $83,832.14 in StockJuly 9, 2024 | investorplace.comThe 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024July 5, 2024 | investorplace.com3 Highly Rated Biotech Stocks for Your July Buy ListJuly 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJune 16, 2024 | seekingalpha.comIncyte: The Worst Has Been AvoidedJune 14, 2024 | gurufocus.comInsider Sale: EVP & General Manager US Barry Flannelly Sells 19,164 Shares of Incyte Corp (INCY)June 13, 2024 | businesswire.comIncyte Announces Final Results of Tender OfferJune 7, 2024 | globenewswire.comMalignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific InterventionsMay 30, 2024 | businesswire.comIncyte Completes Acquisition of Escient PharmaceuticalsSee More Headlines Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$73.25 High Stock Price Target$93.00 Low Stock Price Target$48.00 Potential Upside/Downside+6.8%Consensus RatingHold Rating Score (0-4)2.39 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio20.79 Forward P/E Ratio18.75 P/E Growth1.4Net Income$597.60 million Net Margins19.78% Pretax Margin27.03% Return on Equity12.83% Return on Assets9.80% Debt Debt-to-Equity Ratio0.01 Current Ratio3.47 Quick Ratio3.43 Sales & Book Value Annual Sales$3.70 billion Price / Sales4.17 Cash Flow$2.50 per share Price / Cash Flow27.48 Book Value$23.16 per share Price / Book2.96Miscellaneous Outstanding Shares224,540,000Free Float185,246,000Market Cap$15.41 billion OptionableOptionable Beta0.73 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Herve Hoppenot (Age 64)CEO & Chairman Comp: $2.9MDr. Pablo J. Cagnoni M.D. (Age 61)Ph.D., President and Head of Research & Development Comp: $2.03MMs. Christiana Stamoulis MBA (Age 53)Executive VP & CFO Comp: $1.18MDr. Barry P. Flannelly M.B.A. (Age 66)Pharm.D., Executive VP & GM of North America Comp: $1.01MDr. Steven H. Stein M.D. (Age 57)Executive VP & Chief Medical Officer Comp: $1.32MMr. Thomas Tray (Age 46)VP of Finance, Chief Accounting Officer & Controller Mr. Michael James Morrissey (Age 60)Executive VP & Head of Global Technical Operations Mr. Ben StrainHead of Investor RelationsSheila A. Denton (Age 58)Executive VP, General Counsel & Corporate Secretary Ms. Pamela M. Murphy (Age 73)Vice President of Investor Relations & Corporate Communications More ExecutivesKey CompetitorsMedpaceNASDAQ:MEDPPPDNASDAQ:PPDCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHSyneos HealthNASDAQ:SYNHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 64,347 shares on 7/26/2024Ownership: 0.511%ARK Investment Management LLCSold 40,023 shares on 7/26/2024Ownership: 0.178%State of Michigan Retirement SystemSold 3,500 shares on 7/26/2024Ownership: 0.021%Atlantic Edge Private Wealth Management LLCSold 1,899 shares on 7/26/2024Ownership: 0.010%Catalyst Financial Partners LLCBought 7,299 shares on 7/26/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $62.79 at the beginning of the year. Since then, INCY shares have increased by 9.3% and is now trading at $68.61. View the best growth stocks for 2024 here. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) announced its quarterly earnings data on Tuesday, April, 30th. The biopharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.69 by $0.31. The biopharmaceutical company earned $880.89 million during the quarter, compared to analyst estimates of $935.85 million. Incyte had a trailing twelve-month return on equity of 12.83% and a net margin of 19.78%. What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. Who are Incyte's major shareholders? Incyte's top institutional investors include Bank of New York Mellon Corp (0.51%), Allspring Global Investments Holdings LLC (0.40%), Swedbank AB (0.30%) and Sumitomo Mitsui Trust Holdings Inc. (0.24%). Insiders that own company stock include Steven H Stein, Maria E Pasquale, Barry P Flannelly, Vijay K Iyengar, Thomas Tray, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Wendy L Dixon and Paula J Swain. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and Micron Technology (MU). This page (NASDAQ:INCY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
